The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of ...

The late Dr. David Ahlquist co-invented ColoGuard, which is helping drive Abbott Laboratories’ acquisition of Exact Sciences. After an ALS diagnosis in 2019, Ahlquist wasn’t done inventing.

Jadeja's spin magic guided India to a dominant 337-run victory over South Africa in the 2015 Delhi Test, clinching the series ...

About 3 million glucose monitoring sensors were potentially affected by a production error that caused incorrect low glucose readings.

A high-level delegation from Abbott, led by the company’s Divisional Vice President for EMEA & Global Accounts, has paid a ...

Grail Inc. is downgraded from Speculative Buy to Hold after a rapid share price surge from $55 to $100. Click here to read my ...

The molecular biosensors market is ripe with opportunities due to rising demand for rapid, accurate diagnostics for chronic ...

His 82 against English Test quicks Matthew Potts and Josh Tongue in Canberra followed the cauldron of Mitchell Starc and Josh Hazlewood on a tricky SCG wicket. Kellaway did what only one Englishman ...

The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 ...

NEW YORK – Abbott's $23 billion purchase of Exact Sciences announced last week is expected to strengthen the firm's position in diagnostics and expand the company's reach into the cancer space. The ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Chicago, IL–based healthcare technology giant Abbott Laboratories will acquire Exact Sciences for $23 billion. Exact’s flagship product, Cologuard, is an at-home, stool-based test approved by the FDA ...